Business
NovAccess Global Announces Fireside Chat with Board Member Perspectives
NovAccess Global Announces Fireside Chat with Board Member Perspectives.
About this update from Novaccess Global Inc.
[{"type":"text","content":"Topic: Opportunities for the Biomedical Field and for ShareholdersCLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.The initial fireside chat includes interview with select Executive and Non-Executive members of the Company's Board of Directors. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at https://novaccessglobal.com/news/ and on all of the Company's social media feeds.During the interview made available today, Company speakers address:NovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumorsSignificant unmet need in the glioblastoma/brain tumor marketProgress pathways for NovAccess Global's novel lead product TLR-AD1, including IND and FDA data submissionsRepresenting a new class of immunotherapies shaping the industryEnhanced response and survival potential using the Company's patented platform-based immune booster technologyDriving efficiencies with check point inhibitors for improving tumor treatment outcomesAggressive timeline set to achieve inflection points of safety and efficacy for lead productLicensing opportunities for various cancer treatmentsAccelerating healthcare innovation through technology transferExponential value creation potential for investors available through NovAccess GlobalSpeaker Bios:Dr. Dwain Irvin, Ph.D., MPH, CEO and Executive Board Member of NovAccess Global -- Dr. Irvin is an active participant in many Biotechnology and Health Science endeavors and is an expert including patent generation in such areas as treatments for Parkinson's, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals...